Goby Meds Review
We track Goby Meds but publish no price for it, and this page explains exactly why.
Goby Meds does not publish a tirzepatide price we can interpret and verify from its own material, so we publish none. A figure copied from a third-party round-up without a capture date is not a price, it is a rumour with a dollar sign.
That is not an accusation. Programmes price behind an intake for ordinary commercial reasons. But a comparison site exists to make cost visible before you commit, and a programme that reveals cost only after you have handed over contact details and a health history has opted out of that comparison.
We track this programme but have not been able to verify a tirzepatide price from its own published material. We publish no figure rather than repeat one we cannot check.
Source
No verified price as of 2026-08-05
Of the 32 programmes on this site, 11 have a price we read at the provider or manufacturer, 6 carry a third-party figure we have not confirmed, and 15 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
First-year all-in cost
What to ask Goby Meds before you give them anything
- What is the total monthly cost at a 10 mg maintenance dose, including every fee?
- Does that figure change as the dose escalates?
- Is there a membership, consultation, shipping or laboratory charge on top?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What notice is required to cancel, and what is refundable before shipment?
Answers to those six in writing amount to published pricing, and we will record them here with the date. Send them through contact.
Why a missing price is itself information
A programme that publishes a price is making a claim it can be held to. A programme that reveals cost only after an intake has made a commercial choice: it wants contact details and a medical history before you can compare it against anything. That is legal and common, and worth noticing.
It also makes an honest comparison impossible. Every figure on this site is stated all-in at a named dose, and there is no way to place Goby Meds on that axis without a number from Goby Meds.
What the alternatives publish
The cheapest tracked route, NexLife, publishes $215 a month all-in at a 10 mg maintenance dose and about $2,580 for a first year. Several publish a full ladder from the starter dose to the ceiling. Those figures can be checked against the provider's own page in under a minute, which is the standard Goby Meds is being measured against.
What we will not do
Estimate. Several comparison sites carry figures for programmes that publish none, generally by copying an older round-up that copied an earlier one. That is how a promotional rate from two years ago becomes a current price, and it is the most common error in this category.
A blank row is less useful than a number and considerably more honest than a wrong one.
Programmes that do publish a price
Every other programme in our directory states a figure we could capture at at least one dose tier. The cheapest verified all-in cost at a maintenance dose is $215 a month.
How the price behaves as your dose climbs
Goby Meds starts at — and rises with your prescription, reaching — at 10 mg. The advertised figure therefore describes roughly four weeks of a twelve-month course. Budget from the 10 mg row, because that is where most of your year happens.
Dose-scaled pricing is not misconduct — more active drug does cost a compounder more. But it means your bill rises exactly as the dose starts working, which inverts the incentive you face and is invisible in any table quoting one number.
What a longer horizon costs here
Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.
| If you maintain at | Per month | One year | Three years |
|---|
Commitment, refunds and what is at risk
No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.
Cancellation: not published. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.
What this programme does not publish
Measured against our published criteria, Goby Meds does not publish: price published at every dose tier; price does not rise as the dose escalates; dispensing pharmacy or prescriber named before purchase; prepaid term and its rate published; state availability published; cancellation terms published. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.
Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.
Seven questions before you enrol
- What is the total in month six at 10 mg, including every fee?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What is the vial concentration and the beyond-use date?
- Does the quoted rate hold at renewal, or revert?
- What happens if a shipment arrives warm, and who pays for the replacement?
- What notice is required to cancel, and what is refundable before shipment?
None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.
Using it well if you do enrol
Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.
How much goby meds should weigh
Less than the dose question and more than the brand. 12 of 16 programmes hold one price from 2.5 mg to 10 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.
That is because tirzepatide titrates slowly. Eight to twelve weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.
Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.
What a well-run programme publishes
Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished tirzepatide base from salt forms and linked the salts to safety concerns.
That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.
What stopping does, and why it belongs in a cost calculation
The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.
Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.
Why the same molecule sells across a fifteenfold range
The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.
That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.
What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.
The pharmacology behind the fees
Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.
A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.
What stopping does, and why it belongs in a cost calculation
The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.
Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.
Why the same molecule sells across a fifteenfold range
The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.
That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.
What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.
The pharmacology behind the fees
Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.
A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.